patient
univers
medic
center
utrecht
netherland
referr
center
treatment
hematolog
malign
adult
everi
year
patient
undergo
either
autolog
allogen
sct
octob
may
patient
hematolog
ward
hematolog
outpati
clinic
underw
bronchoalveolar
lavag
bal
select
studi
databas
depart
virolog
sinc
octob
bal
sampl
obtain
patient
hematolog
malign
routin
store
hospit
diagnost
virolog
laboratori
retrospect
studi
adult
hematolog
cancer
also
sign
pneumonia
radiograph
pulmonari
abnorm
whose
bal
sampl
store
consid
assess
review
patient
chart
obtain
follow
inform
underli
diseas
therapi
antimicrobi
treatment
addit
bacteri
fungal
viral
cultur
data
antigen
test
result
serolog
data
clinic
featur
outcom
total
bal
specimen
patient
investig
routin
follow
pathogen
bacteria
mycobacteria
fungi
herpesvirus
respiratori
virus
influenza
virus
rsv
parainfluenza
virus
picornavirus
adenovirus
nosethroat
nt
swab
also
obtain
patient
within
week
bal
sampl
nt
swab
also
store
convent
test
respiratori
virus
addit
pair
serum
sampl
obtain
patient
detect
atyp
bacteri
eg
mycoplasma
pneumonia
chlamydia
speci
legionella
speci
respiratori
viru
pathogen
store
bal
sampl
nt
swab
subsequ
analyz
use
pcr
techniqu
detect
respiratori
virus
sct
regimen
infect
prophylaxi
infectionprevent
measur
patient
expect
durat
neutropenia
day
receiv
antibacteri
prophylaxi
oral
administ
ciprofloxacin
mg
twice
per
day
oral
administ
antifung
prophylaxi
amphotericin
b
tablet
mg
time
per
day
fluconazol
mg
per
day
antimicrobi
regimen
continu
granulocyt
count
increas
cellsl
prevent
bacteremia
caus
streptococci
patient
receiv
clindamycin
mg
time
per
day
neutropenia
case
highdos
cytarabin
patient
undergo
sct
receiv
intraven
cephalothin
g
time
per
day
transplant
neutropenia
patient
underw
allogen
sct
routin
receiv
valacyclovir
mg
twice
per
day
cotrimoxazol
mg
per
day
first
month
transplant
addit
patient
posit
result
cytomegaloviru
test
first
month
underw
allogen
sct
receiv
preemptiv
therapi
ganciclovir
hospit
patient
care
singl
room
free
entri
staff
visitor
care
hand
wash
use
lowmicrobialcount
food
prevent
measur
use
patient
pulmonari
infect
consid
hospit
acquir
symptom
develop
day
admiss
diagnost
method
routin
detect
respiratori
viru
pathogen
nasopharyng
throat
swab
place
viral
transport
media
bal
sampl
place
tube
contain
viru
transport
medium
obtain
viral
cultur
either
transport
laboratori
immedi
store
maximum
h
materi
divid
frozen
store
analysi
pcr
directli
use
viral
cultur
cultur
perform
inocul
rhela
tertiari
monkey
kidney
tmk
cell
clinic
sampl
detect
respiratori
virus
adenovirus
parainfluenza
virus
rsv
influenza
virus
picornavirus
cultur
examin
cytopath
effect
twice
per
week
day
posit
cultur
viru
identifi
immunofluoresc
commerci
monoclon
antibodi
dako
imagen
influenza
b
virus
rsv
parainfluenza
virus
adenovirus
rhinovirus
distinguish
enterovirus
mean
acidl
test
rapid
antigen
test
perform
day
cultur
usual
cytopath
effect
could
notic
immunofluoresc
microscopi
use
virusspecif
monoclon
antibodi
dako
imagen
use
detect
rsv
parainfluenza
virus
influenza
b
virus
adenovirus
pair
serum
sampl
use
serolog
detect
respiratori
viral
ill
posit
diagnosi
defin
increas
virusspecif
antibodi
titer
standard
serolog
test
complement
fixat
use
rsv
influenza
b
parainfluenza
viru
adenoviru
infect
addit
indirect
immunofluoresc
assay
use
detect
rsv
influenza
b
rna
extract
clinic
specimen
nest
pcr
pcr
perform
detect
influenza
b
viru
parainfluenza
virus
picornavirus
rhinoviru
enteroviru
rsv
coronavirus
store
bal
sampl
obtain
patient
nt
swab
obtain
patient
nt
swab
obtain
within
week
bal
primer
obtain
literatur
select
genbank
conserv
region
gene
matrix
protein
influenza
viru
hemagglutinin
gene
influenza
b
viru
noncod
region
picornavirus
nucleocapsid
protein
rsv
b
hemagglutininneuraminidas
glycoprotein
parainfluenza
nucleocapsid
protein
coronaviru
nucleic
acid
extract
perform
patient
materi
accord
method
boom
et
al
pcr
reaction
rtpcr
follow
nest
pcr
essenti
describ
nijhui
et
al
modif
method
consist
optim
separ
pcr
reaction
serial
dilut
primer
concentr
pcr
perform
pe
thermocycl
abi
rhinovirus
identifi
bgli
digest
picornaviru
rtpcr
amplicon
pcr
product
visual
ethidium
agaros
gel
use
ultraviolet
illumin
statist
analysi
descript
statist
express
median
valu
analysi
perform
determin
degre
signific
variou
variabl
patient
characterist
demograph
characterist
underli
diseas
condit
therapi
use
prophylaxi
immunolog
statu
patient
shown
tabl
major
patient
present
sign
symptom
respiratori
diseas
fever
patient
cough
short
breath
common
complaint
ten
patient
develop
sign
symptom
pneumonia
time
hospit
admiss
patient
develop
communityacquir
pneumonia
twentyeight
patient
undergon
sct
median
durat
transplant
onset
symptom
respiratori
diseas
month
rang
month
twentysix
patient
develop
pneumonia
winter
season
detect
respiratori
virus
mean
cultur
antigen
test
respiratori
virus
identifi
patient
rsv
rhinovirus
influenza
virus
respiratori
virus
detect
nest
rtpcr
one
patient
infect
respiratori
viru
twice
initi
patient
admit
pneumonia
caus
rsv
subsid
spontan
within
day
patient
still
inpati
hospit
develop
nosocomi
pneumonia
week
later
caus
cultureproven
influenza
addit
respiratori
virus
detect
pcr
anoth
patient
tabl
one
patient
dual
infect
rhinoviru
parainfluenza
viru
total
respiratori
virus
detect
pcr
patient
compar
respiratori
virus
patient
detect
cultur
antigen
test
p
pair
serum
sampl
avail
patient
serolog
test
show
increas
rsvspecif
igg
antibodi
titer
patient
increas
titer
adenoviru
patient
combin
nt
swab
obtain
patient
within
week
bal
sampl
patient
respiratori
viru
diseas
sampl
nt
bal
avail
nest
rtpcr
nt
sampl
alway
yield
result
bal
sampl
tabl
caus
pneumonia
patient
caus
pneumonia
found
tabl
respiratori
viru
pathogen
could
detect
patient
patient
respiratori
viru
pathogen
detect
anoth
caus
pulmonari
infect
lung
injuri
clinic
probabl
two
patient
thought
pneumonia
caus
bacterium
respiratori
viru
staphylococcu
aureu
rhinoviru
one
patient
haemophilu
influenza
rhinoviru
anoth
patient
proven
aspergillu
fumigatu
probabl
pulmonari
fungal
infect
togeth
infect
enteroviru
influenza
viru
respect
anoth
patient
posttransplant
lymphoprolif
diseas
pulmonari
involv
receiv
stem
cell
transplant
match
unrel
donor
combin
enteroviru
infect
patient
coronaviru
detect
addit
bronchiol
obliteran
four
patient
pneumonia
probabl
caus
patient
patient
bacteria
enterobact
speci
pseudomona
speci
h
influenza
stenotrophomona
maltophilia
isol
patient
total
patient
proven
patient
probabl
pulmonari
infect
fungi
five
patient
caus
pulmonari
diseas
one
patient
progress
epsteinbarr
posttransplant
lymphoprolif
diseas
pulmonari
involv
receiv
stem
cell
transplant
match
unrel
donor
patient
bronchiol
obliteran
anoth
patient
cytomegaloviru
pneumon
patient
develop
toxic
lung
injuri
transplant
treatment
two
patient
rsv
pneumonia
treat
aerosol
ribavirin
g
time
per
day
minimum
day
start
ribavirin
treatment
patient
symptom
upper
respiratori
tract
infect
week
patient
recov
complet
week
treatment
anoth
patient
also
recov
rsv
pneumonia
without
administr
ribavirin
one
patient
die
patient
contact
rsv
pneumonia
recurr
acut
myelogen
leukemia
shortli
receiv
allogen
stem
cell
transplant
match
unrel
donor
also
patient
receiv
treatment
diagnosi
made
posit
pcr
result
rsv
death
comparison
patient
pneumonia
without
respiratori
viru
patient
pneumonia
caus
respiratori
viru
compar
patient
pneumonia
caus
respiratori
viru
regard
follow
characterist
underli
diseas
treatment
immun
statu
use
immunosuppress
sign
symptom
type
specimen
obtain
presenc
nosocomi
communityacquir
respiratori
diseas
time
transplant
period
year
acquir
infect
tabl
signific
differ
paramet
group
although
seem
tendenc
toward
male
patient
use
immunosuppress
presenc
neutropenia
group
patient
pneumonia
caus
respiratori
viru
major
case
respiratori
pneumonia
occur
winter
season
wherea
occurr
pneumonia
without
detect
respiratori
viru
spread
equal
throughout
year
case
occur
winter
month
vs
case
summer
month
patient
hematolog
cancer
pneumonia
store
bal
sampl
yield
significantli
respiratori
virus
nest
rtpcr
perform
compar
standard
cultur
rapid
cultur
serolog
test
valu
case
acut
rsv
infect
case
adenoviru
infect
result
indic
previou
studi
reli
viral
cultur
antigen
test
determin
incid
role
respiratori
virus
patient
group
may
underestim
true
incid
past
decad
respiratori
virus
increasingli
recogn
caus
agent
respiratori
tract
infect
sever
immunocompromis
patient
high
frequenc
nosocomi
acquisit
persist
infect
beyond
time
period
report
immunocompet
patient
high
frequenc
pneumonia
death
found
associ
respiratori
viru
infect
immunocompromis
patient
studi
pcr
found
rel
high
incid
respiratori
pneumonia
immunocompromis
patient
report
incid
respiratori
viru
infect
adult
bone
marrow
transplant
recipi
acut
upper
lower
respiratori
ill
immunocompromis
patient
rate
howev
confirm
report
high
frequenc
nosocomi
acquisit
find
high
rate
death
due
respiratori
pneumonia
overal
studi
publish
elsewher
rsv
account
major
respiratori
viru
infect
high
mortal
rate
rsvrelat
mortal
rate
high
report
hospit
adult
patient
leukemia
rate
high
person
undergo
sct
prompt
therapi
rsv
infect
aerosol
ribavirin
without
intraven
immunoglobulin
appear
impact
favor
frequenc
progress
pneumonia
death
studi
random
control
studi
lack
data
studi
consist
previou
studi
shown
rsv
preval
respiratori
viru
person
respiratori
pneumonia
mortal
rate
studi
howev
influenza
parainfluenza
virus
also
report
frequent
immunocompromis
patient
communityoutbreak
period
respiratori
virus
particular
parainfluenza
viru
infect
may
import
caus
lifethreaten
pneumonia
patient
undergo
sct
receiv
treatment
leukemia
mortal
rate
incid
sever
pneumonia
immunocompromis
patient
caus
influenza
viru
vari
sever
studi
one
studi
influenza
isol
person
underw
sct
acut
respiratori
ill
complic
pneumonia
patient
pneumoniaassoci
mortal
rate
studi
research
conclud
influenza
viru
immunocompromis
patient
occasion
caus
sever
complic
often
mild
selflimit
found
patient
influenza
pneumonia
patient
parainfluenza
viru
infect
none
patient
receiv
antivir
therapi
recov
without
sequela
recent
rhinovirus
also
identifi
pathogen
potenti
infect
lower
respiratori
tract
ghosh
et
al
describ
case
rhinovirusassoci
infect
myelosuppress
adult
blood
bone
marrow
transplant
recipi
earli
transplant
develop
fatal
pneumonia
studi
rhinovirus
detect
mean
convent
method
interest
use
molecular
diagnost
document
increas
involv
rhinovirus
virusassoci
pneumonia
indic
rhinovirus
may
play
seriou
role
caus
pneumonia
immunocompromis
patient
detect
coronaviru
sampl
obtain
one
immunocompromis
patient
observ
line
find
anoth
studi
demonstr
pneumonia
caus
coronaviru
occur
patient
receiv
autolog
bone
marrow
transplant
treat
breast
cancer
also
analyz
sampl
presenc
enteroviru
although
lower
respiratori
tract
usual
site
enteroviru
infect
howev
immunocompromis
patient
pneumonia
presenc
enteroviru
bal
specimen
demonstr
sever
studi
result
confirm
studi
patient
reveal
presenc
enteroviru
therebi
demonstr
infect
consid
caus
pneumonia
sever
immunocompromis
patient
although
method
detect
adenoviru
pcr
describ
elsewher
detect
adenoviru
infect
serolog
test
found
increas
serum
titer
adenoviru
patient
adenovirus
detect
standard
cultur
antigen
detect
gener
pcr
adenoviru
infect
yet
avail
laboratori
still
limit
consid
pcr
use
diagnost
tool
detect
respiratori
virus
first
complet
rule
contamin
bal
sampl
upper
respiratori
tract
state
found
concord
pcr
result
bal
nt
sampl
thu
rule
possibl
contamin
howev
uncertainti
intrins
relat
use
bal
second
rule
possibl
posit
pcr
result
littl
clinic
signific
sever
immunocompromis
patient
known
shed
viru
long
period
time
therefor
exact
mean
posit
pcr
result
still
need
determin
prospect
studi
differ
antivir
agent
avail
develop
treatment
rsv
influenza
viru
rhinoviru
infect
import
improv
method
rapidli
diagnos
respiratori
ill
caus
respiratori
virus
immunocompromis
patient
rapid
sensit
method
detect
respiratori
virus
essenti
implement
prompt
measur
start
treatment
soon
possibl
patient
risk
develop
pneumonia
caus
respiratori
virus
prevent
limit
nosocomi
spread
infect
show
pcr
might
import
tool
accomplish
goal
conclus
shown
molecular
diagnost
techniqu
significantli
increas
detect
rate
respiratori
virus
patient
hematolog
cancer
pneumonia
compar
tradit
method
howev
prospect
surveil
studi
still
necessari
establish
clinic
valu
techniqu
